Fluticasone Propionate And Salmeterol Powder
Product Images NDC 68788-8704

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 68788-8704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figurec.jpg (Figurec)

Illustration showing hands holding an inhaler device, demonstrating a twisting or turning motion indicated by a large arrow. The inhaler has a visible dose counter displaying the number 60 on its front.*

FDA Label Image

Figuref.jpg (Figuref)

Illustration showing hands holding a respiratory inhalation device, specifically a fluticasone propionate and salmeterol powder inhaler, with an arrow indicating to rotate or turn the blue dose counter dial marked with the number 59.*

FDA Label Image

Figureh.jpg (Figureh)

An instructional illustration showing a respiratory inhalation device for fluticasone propionate and salmeterol powder. The image highlights a close-up view of a dose counter window on the device displaying the number 5 in red, indicating the remaining doses.*

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

Chemical structure of fluticasone propionate, one of the active ingredients in fluticasone propionate and salmeterol respiratory powder inhalation product.*

FDA Label Image

Figure-5-08172021.jpg (Image 03)

A line graph showing the percent change in FEV1 over 24 weeks comparing three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg twice daily, Fluticasone Propionate 250 mcg twice daily, and Placebo. The x-axis represents time from day 1 to week 24, and the y-axis represents percent change in FEV1. The combination treatment group shows the highest improvement, followed by fluticasone alone, with the placebo group showing the least change.*

FDA Label Image

Figure-4.jpg (Image 04)

Line graph showing percent change in FEV1 (forced expiratory volume) over 24 weeks and endpoint comparing three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The Fluticasone Propionate and Salmeterol group shows the highest sustained increase, Salmeterol group shows moderate increase, and Placebo shows minimal change. The graph includes baseline FEV1 values and subject numbers at different time points.*

FDA Label Image

Figure-1a (Image 05)

A line graph showing the percentage change in FEV1 over 12 weeks for four treatments: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The x-axis represents weeks 0 to 12, and the y-axis represents percent change in FEV1, ranging from -5 to 30. A data table below the graph shows the number of subjects (N) per treatment group at various weeks and endpoint.*

FDA Label Image

Figure-2.jpg (Image 06)

A line graph showing the percent change in FEV1 over 12 hours on the first treatment day for four groups: Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, and placebo. The x-axis represents time in hours after baseline, and the y-axis represents percentage change in FEV1, with the combination therapy group showing the highest peak improvement.*

FDA Label Image

Figure-3a (Image 07)

A line graph illustrating percentage change in FEV1 relative to Day 1 baseline over 12 hours on the last treatment day (Week 12) for fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo groups. The x-axis shows time in hours, and the y-axis shows percent change in FEV1 with corresponding trends for each treatment group.*

FDA Label Image

Fluticasone Prop Salmeterol Inh Powder 100mcg50mcg (Image 09)

Packaging label for fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg by Preferred Pharmaceuticals Inc. The label includes dosage form as powder for respiratory inhalation, warnings, manufacturer information (West-Ward Columbus Inc.), barcode, and bilingual directions in English and Spanish. The label highlights it as a generic for Advair HFA and includes space for lot number, batch number, expiration date, and insurance NDC.*

FDA Label Image

Image1.jpg (Image1)

An instructional diagram of a fluticasone propionate and salmeterol inhalation powder device showing labeled parts: Outer Case, Mouthpiece, Counter, Thumb Grip, and Lever. The top label displays the product name, strength of 100 mcg/50 mcg, and 60 blisters in the device.*

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

Chemical structure diagram depicting the active ingredients fluticasone propionate and salmeterol. The image shows detailed molecular formulas of both compounds used in the respiratory inhalation powder product by Preferred Pharmaceuticals Inc.*

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

Instructional illustration showing how to hold and rotate a respiratory inhaler device with a visible dose counter displaying '60'. The image demonstrates correct handling or priming of the inhaler for administration of fluticasone propionate and salmeterol powder for inhalation.*

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

An instructional illustration showing a person holding a respiratory inhalation device near their mouth. The user appears to be preparing to inhale powder medication from the device, demonstrating proper technique for administering fluticasone propionate and salmeterol powder via inhalation.*

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

Illustration of a person using an inhaler device for respiratory administration of medication. The individual is holding the inhaler close to their mouth, demonstrating the proper use of a powder inhaler typically used for delivering drugs such as fluticasone propionate and salmeterol.*

FDA Label Image

Ww-image-7.jpg (Ww Image 7)

An instructional illustration showing a person spitting out liquid into a sink, with a glass of water nearby, likely demonstrating proper use or rinsing after inhalation treatment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.